Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma

  • Jiménez, Rafael|||0000-0003-4103-8219
  • Constantinescu, Andrada
  • Yazir, Muhube
  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Pequerul Pavón, Raquel|||0000-0002-0008-975X
  • Parés i Casasampera, Xavier|||0000-0002-5071-9465
  • Pérez-Alea, Mileidys|||0000-0002-8739-8087
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Farrés, Jaume|||0000-0001-9069-3987
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
Glioblastoma (GB) is an aggressive malignant central nervous system tumor that is currently incurable. One of the main pitfalls of GB treatment is resistance to the chemotherapeutic standard of care, temozolomide (TMZ). The role of aldehyde dehydrogenases (ALDHs) in the glioma stem cell (GSC) subpopulation has been related to chemoresistance. ALDHs take part in processes such as cell proliferation, differentiation, invasiveness or metastasis and have been studied as pharmacological targets in cancer treatment. In the present work, three novel α,β-acetylenic amino thiolester compounds, with demonstrated efficacy as ALDH inhibitors, were tested in vitro on a panel of six human GB cell lines and one murine GB cell line. Firstly, the expression of the ALDH1A isoforms was assessed, and then inhibitors were tested for their cytotoxicity and their ability to inhibit cellular ALDH activity. Drug combination assays with TMZ were performed, as well as an assessment of the cell death mechanism and generation of ROS. A knockout of several ALDH genes was carried out in one of the human GB cell lines, allowing us to discuss their role in cell proliferation, migration capacity and resistance to treatment. Our results strongly suggest that ALDH inhibitors could be an interesting approach in the treatment of GB, with EC50 values in the order of micromolar, decreasing ALDH activity in GB cell lines to 40-50%.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images

  • Wu, Shuang|||0000-0001-7618-5476
  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Villamañán de Santiago, Lucía|||0000-0002-6702-2103
  • Arias-Ramos, Nuria|||0000-0001-8983-6362
  • Pumarola i Batlle, Martí|||0000-0002-0935-7941
  • Ortega-Martorell, Sandra|||0000-0001-9927-3209
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
Glioblastomas (GB) are brain tumours with poor prognosis even after aggressive therapy. Improvements in both therapeutic and follow-up strategies are urgently needed. In previous work we described an oscillatory pattern of response to Temozolomide (TMZ) using a standard administration protocol, detected through MRSI-based machine learning approaches. In the present work, we have introduced the Immune-Enhancing Metronomic Schedule (IMS) with an every 6-d TMZ administration at 60 mg/kg and investigated the consistence of such oscillatory behaviour. A total of n = 17 GL261 GB tumour-bearing C57BL/6j mice were studied with MRI/MRSI every 2 d, and the oscillatory behaviour (6.2 ± 1.5 d period from the TMZ administration day) was confirmed during response. Furthermore, IMS-TMZ produced significant improvement in mice survival (22.5 ± 3.0 d for controls vs 135.8 ± 78.2 for TMZ-treated), outperforming standard TMZ treatment. Histopathological correlation was investigated in selected tumour samples (n = 6) analyzing control and responding fields. Significant differences were found for CD3+ cells (lymphocytes, 3.3 ± 2.5 vs 4.8 ± 2.9, respectively) and Iba-1 immunostained area (microglia/macrophages, 16.8% ± 9.7% and 21.9% ± 11.4%, respectively). Unexpectedly, during IMS-TMZ treatment, tumours from some mice (n = 6) fully regressed and remained undetectable without further treatment for 1 mo. These animals were considered "cured" and a GL261 re-challenge experiment performed, with no tumour reappearance in five out of six cases. Heterogeneous therapy response outcomes were detected in tumour-bearing mice, and a selected group was investigated (n = 3 non-responders, n = 6 relapsing tumours, n = 3 controls). PD-L1 content was found ca. 3-fold increased in the relapsing group when comparing with control and non-responding groups, suggesting that increased lymphocyte inhibition could be associated to IMS-TMZ failure. Overall, data suggest that host immune response has a relevant role in therapy response/escape in GL261 tumours under IMS-TMZ therapy. This is associated to changes in the metabolomics pattern, oscillating every 6 d, in agreement with immune cycle length, which is being sampled by MRSI-derived nosological images.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Extraction of artefactual MRS patterns from a large database using non-negative matrix factorization

  • Hernández-Villegas, Yanisleydis|||0000-0002-4309-5113
  • Ortega-Martorell, Sandra|||0000-0001-9927-3209
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Vellido, Alfredo|||0000-0002-9843-1911
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
Despite the success of automated pattern recognition methods in problems of human brain tumor diagnostic classification, limited attention has been paid to the issue of automated data quality assessment in the field of MRS for neuro-oncology. Beyond some early attempts to address this issue, the current standard in practice is MRS quality control through human (expert-based) assessment. One aspect of automatic quality control is the problem of detecting artefacts in MRS data. Artefacts, whose variety has already been reviewed in some detail and some of which may even escape human quality control, have a negative influence in pattern recognition methods attempting to assist tumor characterization. The automatic detection of MRS artefacts should be beneficial for radiology as it guarantees more reliable tumor characterizations, as well as the development of more robust pattern recognition-based tumor classifiers and more trustable MRS data processing and analysis pipelines. Feature extraction methods have previously been used to help distinguishing between good and bad quality spectra to apply subsequent supervised pattern recognition techniques. In this study, we apply feature extraction differently and use a variant of a method for blind source separation, namely Convex Non-Negative Matrix Factorization, to unveil MRS signal sources in a completely unsupervised way. We hypothesize that, while most sources will correspond to the different tumor patterns, some of them will reflect signal artefacts. The experimental work reported in this paper, analyzing a combined short and long echo time 1H-MRS database of more than 2000 spectra acquired at 1.5T and corresponding to different tumor types and other anomalous masses, provides a first proof of concept that points to the possible validity of this approach.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Machine Learning Analysis of Single-Voxel Proton MR Spectroscopy for Differentiating Solitary Fibrous Tumors and Meningiomas

  • Toth, Lili Fanni|||0000-0002-4553-292X
  • Majos, Carles|||0000-0003-0468-5150
  • Pons-Escoda, Albert|||0000-0003-4167-8291
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
Solitary fibrous tumor (SFT), formerly known as hemangiopericytoma, is an uncommon brain tumor often confused with meningioma on MRI. Unlike meningiomas, SFTs exhibit a myoinositol peak on magnetic resonance spectroscopy (MRS). This study aimed to develop automated classifiers to distinguish SFT from meningioma grades using MRS data from a 26-year patient cohort. Four classification tasks were performed on short echo (SE), long echo (LE) time, and concatenated SE + LE spectra, with datasets split into 80% training and 20% testing sets. Sequential forward feature selection and linear discriminant analysis identified features to distinguish between meningioma Grade 1 (Men-1), meningioma grade 2 (Men-2), meningioma grade 3 (Men-3), and SFT (the 4-class classifier); Men-1 from Men-2 + 3 + SFT; meningioma (all) from SFT; and Men-1 from Men-2 + 3 and SFT. The best classifier was defined by the smallest balanced error rate (BER) in the testing phase. A total of 136 SE cases and 149 LE cases were analyzed. The best features in the 4-class classifier were myoinositol and alanine at SE, and myoinositol, glutamate, and glutamine at LE. Myoinositol alone distinguished SFT from meningiomas. Differentiating Men-1 from Men-2 was not possible with MRS, and combining higher meningioma grades did not improve distinction from Men-1. Notably, combining short and long echo times (TE) enhances classification performance, particularly in challenging outlier cases. Furthermore, the robust classifier demonstrates efficacy even when dealing with spectra of suboptimal quality. The resulting classifier is available as Supporting Information of the publication. Extensive documentation is provided, and the software is free and open to all users without a login requirement.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Improved MRSI in a Murine Glioma Model Using semiLASER, Refining the Metabolomics Data Obtained from Murine Models

  • Javed, Zoona|||0009-0009-8279-9744
  • Martinez, Gary V.|||0000-0002-6204-8363
  • Mulero-Acevedo, Marta|||0000-0002-3600-8907
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Cabañas Egaña, Miquel|||0000-0003-0104-0197
  • Lope-Piedrafita, Silvia|||0000-0002-8127-6425
Background: Magnetic resonance spectroscopic imaging (MRSI) offers valuable metabolic information for assessing brain tumor progression and therapeutic response, but its performance in rodent models is often hindered by the low signal-to-noise ratio (SNR) and spatially heterogeneous spectral quality, particularly in peripheral voxels. These issues reduce the number of usable spectra available for quantitative and classifier-based analyses. To address this, we implemented a multi-voxel MRSI-semiLASER sequence-widely recommended in clinical practice-on a 7T Bruker Biospec system running ParaVision 5.1 to improve spectral homogeneity in mouse brain tumor studies. Results: Compared with the vendor CSI-PRESS sequence, MRSI-semiLASER produced more uniform spectra across the grid and achieved up to a 1.2-fold SNR increase in murine glioma, enabling a 20% reduction in slice thickness without compromising spectral quality. Importantly, the sequence produced a substantial gain in the proportion of spectra amenable to analysis, particularly in outer grid voxels that frequently fail with CSI-PRESS. The implemented MRSI-semiLASER sequence and instructions are openly available to the community. Conclusions: MRSI-semiLASER improves spectral homogeneity, increases the proportion of usable spectra, and supports higher spatial detail. These technical improvements may enhance data yield per subject and may facilitate future applications such as more robust pattern recognition workflows and greater data efficiency in longitudinal studies, although such aspects were not evaluated here.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Anti-PD-1 immunotherapy in preclinical GL261 glioblastoma, influence of therapeutic parameters and noninvasive response biomarker assessment with MRSI-based approaches

  • Wu, Shuang|||0000-0001-7618-5476
  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
Glioblastomas (GBs) are malignant brain tumours with poor prognosis even after aggressive therapy. Programmed cell death-1 (PD-1) immune checkpoint blockade is a promising strategy in many types of cancer, but its therapeutic effects in GB remain low and associated with immune infiltration. Previous work suggests that oscillations of magnetic resonance spectroscopic imaging (MRSI)-based response pattern with chemotherapy could act as a biomarker of efficient immune system attack onto GBs. The presence of such oscillations with other monotherapies such as anti-PD-1 would reinforce its monitoring potential. Here, we confirm that the oscillatory behaviour of the response biomarker is also detected in mice treated with anti PD-1 immunotherapy both in combination with temozolomide and as monotherapy. This indicates that the spectral pattern changes observed during therapy response are shared by different therapeutic strategies, provided the host immune system is elicited and able to productively attack tumour cells. Moreover, the participation of the immune system in response is also supported by the rate of cured animals observed with different therapeutic strategies (in the range of 50-100% depending on the treatment), which also held long-term immune memory against tumour cells re-challenge. Taken together, our findings open the way for a translational use of the MRSI-based biomarker in patient-tailored GB therapy, including immunotherapy, for which reliable non-invasive biomarkers are still missing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Successful partnerships, exploring the potential of immunogenic signals triggered by TMZ, CX-4945 and combined treatment in GL261 glioblastoma cells

  • Villamañán de Santiago, Lucía|||0000-0002-6702-2103
  • Martínez-Escardó, Laura|||0000-0003-2979-4804
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Yuste, Victor José|||0000-0001-5322-9261
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
The relevance of the cancer immune cycle in therapy response implies that successful treatment may trigger the exposure or the release of immunogenic signals. Previous results with the preclinical GL261 glioblastoma (GB) showed that combination treatment of temozolomide (TMZ) + CX-4945 (protein kinase CK2 inhibitor) outperformed single treatments, provided an immune-friendly schedule was followed. Our purpose was to study possible immunogenic signals released in vitro by GB cells. Methods: GL261 GB cells were treated with TMZ and CX-4945 at different concentrations (25 µM-4 mM) and time frames (12-72 h). Cell viability was measured with Trypan Blue and propidium iodide. Calreticulin exposure was assessed with immunofluorescence, and ATP release was measured with bioluminescence. Results: TMZ showed cytostatic rather than cytotoxic effects, while CX-4945 showed remarkable cytotoxic effects already at low concentrations. Calreticulin exposure after 24 h was detected with TMZ treatment, as well as TMZ/CX-4945 low concentration combined treatment. ATP release was significantly higher with CX-4945, especially at high concentrations, as well as with TMZ/CX-4945. Conclusions: combined treatment may produce the simultaneous release of two potent immunogenic signals, which can explain the outperformance over single treatments in vivo. A word of caution may be raised since in vitro conditions are not able to mimic pharmacokinetics observed in vivo fully.
Dipòsit Digital de Documents de la UAB
Datos de investigación Set de datos (Dataset)

qPCR values of control and TMZ-treated GL261 GB samples

  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Wu, Shuang|||0000-0001-7618-5476
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
This dataset is composed by 20 GL261 GB samples, n=10 from control mice and n=10 of IMS-TMZ treated, responding mice. Samples were extracted and analyzed by qPCR for gene expression levels related to macrophage polarization (Nos2 and CD206), programmed cell death-1 ligand-1 expression (PDL1), as well as 2 housekeeping genes for normalization.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immune system-related changes in preclinical GL261 glioblastoma under TMZ treatment, Explaining MRSI-based nosological imaging findings with RT-PCR analyses

  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Wu, Shuang|||0000-0001-7618-5476
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
Glioblastomas (GB) are brain tumours with poor prognosis even after aggressive therapy. Previous work suggests that magnetic resonance spectroscopic imaging (MRSI) could act as a biomarker of efficient immune system attack onto GB, presenting oscillatory changes. Glioma-associated microglia/macrophages (GAMs) constitute the most abundant non-tumour cell type within the GB and can be polarised into anti-tumour (M1) or pro-tumour (M2) phenotypes. One of the mechanisms to mediate immunosuppression in brain tumours is the interaction between programmed cell death-1 ligand 1 (PD-L1) and programmed cell death-1 receptor (PD-1). We evaluated the subpopulations of GAMs in responding and control GB tumours to correlate PD-L1 expression to GAM polarisation in order to explain/validate MRSI-detected findings. Mice were evaluated by MRI/MRSI to assess the extent of response to treatment and with qPCR for GAMs M1 and M2 polarisation analyses. M1/M2 ratios and PD-L1 expression were higher in treated compared to control tumours. Furthermore, PD-L1 expression was positively correlated with the M1/M2 ratio. The oscillatory change in the GAMs prevailing population could be one of the key causes for the differential MRSI-detected pattern, allowing this to act as immune system activity biomarker in future work.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment

  • Mao, Xiaoman
  • Wu, Shuang|||0000-0001-7618-5476
  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Bruna, Jordi|||0000-0001-6895-5047
  • Yuste, Victor José|||0000-0001-5322-9261
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Novio, Fernando|||0000-0002-1517-3612
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
Glioblastoma is the most malignant and frequently occurring type of brain tumors in adults. Its treatment has been greatly hampered by the difficulty to achieve effective therapeutic concentration in the tumor sites due to its location and the blood-brain barrier. Intranasal administration has emerged as an alternative for drug delivery into the brain though mucopenetration, and rapid mucociliary clearance still remains an issue to be solved before its implementation. To address these issues, based on the intriguing properties of proteins secreted by mussels, polyphenol and catechol functionalization has already been used to promote mucopenetration, intranasal delivery and transport across the blood-brain barrier. Thus, herein we report the synthesis and study of complex 1, a Pt(IV) prodrug functionalized with catecholic moieties. This complex considerably augmented solubility in contrast to cisplatin and showed a comparable cytotoxic effect on cisplatin in HeLa, 1Br3G and GL261 cells. Furthermore, preclinical in vivo therapy using the intranasal administration route suggested that it can reach the brain and inhibit the growth of orthotopic GL261 glioblastoma. These results open new opportunities for catechol-bearing anticancer prodrugs in the treatment for brain tumors via intranasal administration.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response, challenges, Obstacles and Future Perspectives

  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
This hypothesis proposal addresses three major questions: (1) Why do we need imaging biomarkers for assessing the efficacy of immune system participation in glioblastoma therapy response? (2) Why are they not available yet? and (3) How can we produce them? We summarize the literature data supporting the claim that the immune system is behind the efficacy of most successful glioblastoma therapies but, unfortunately, there are no current short-term imaging biomarkers of its activity. We also discuss how using an immunocompetent murine model of glioblastoma, allowing the cure of mice and the generation of immune memory, provides a suitable framework for glioblastoma therapy response biomarker studies. Both magnetic resonance imaging and magnetic resonance-based metabolomic data (i.e., magnetic resonance spectroscopic imaging) can provide non-invasive assessments of such a system. A predictor based in nosological images, generated from magnetic resonance spectroscopic imaging analyses and their oscillatory patterns, should be translational to clinics. We also review hurdles that may explain why such an oscillatory biomarker was not reported in previous imaging glioblastoma work. Single shot explorations that neglect short-term oscillatory behavior derived from immune system attack on tumors may mislead actual response extent detection. Finally, we consider improvements required to properly predict immune system-mediated early response (1-2 weeks) to therapy. The sensible use of improved biomarkers may enable translatable evidence-based therapeutic protocols, with the possibility of extending preclinical results to human patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy

  • Mao, Xiaoman
  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Montpeyó, David|||0000-0002-0327-2015
  • Bruna, Jordi|||0000-0001-6895-5047
  • Yuste, Victor José|||0000-0001-5322-9261
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Novio, Fernando|||0000-0002-1517-3612
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
Cisplatin has been described as a potent anticancer agent for decades. However, in the case of glioblastomas, it is only considered a rescue treatment applied after the failure of second-line treatments. Herein, based on the versatility offered by coordination chemistry, we engineered nanoparticles by reaction of a platinum (IV) prodrug and iron metal ions showing in vitro dual pH- and redox-sensitivity, controlled release and comparable cytotoxicity to cisplatin against HeLa and GL261 cells. In vivo intranasal administration in orthotopic preclinical GL261 glioblastoma tumor-bearing mice demonstrated increased accumulation of platinum in tumors, leading in some cases to complete cure and prolonged survival of the tested cohort. This was corroborated by a magnetic resonance imaging follow-up, thus opening new opportunities for intranasal glioblastoma therapies while minimizing side effects. The findings derived from this research showed the potentiality of this approach as a novel therapy for glioblastoma treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tracking Therapy Response in Glioblastoma Using 1D Convolutional Neural Networks

  • Ortega-Martorell, Sandra|||0000-0001-9927-3209
  • Olier, Iván|||0000-0002-5679-7501
  • Hernandez, Orlando
  • Restrepo-Galvis, Paula D.
  • Bellfield, Ryan A. A.|||0000-0002-9945-914X
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
Glioblastoma (GB) is a malignant brain tumour with no cure, even after the best treatment. The evaluation of a therapy response is usually based on magnetic resonance imaging (MRI), but it lacks precision in early stages, and doctors must wait several weeks until they are confident information is produced, facing an uncertain time window. Magnetic resonance spectroscopy (MRS/MRSI) can provide additional information about tumours and their environment but is not widely used in clinical settings since the spectroscopy format is not standardised as MRI is, and doctors are not familiarised with outputs/interpretation. This study aims to improve the assessment of the treatment response in GB using MRSI data and machine learning, including state-of-the-art one-dimensional convolutional neural networks. Preclinical (murine) GB data were used for developing models that successfully identified tumour regions regarding their response to treatment (or the lack thereof). These models were accurate and outperformed previous methods, potentially providing new opportunities for GB patient management. Background: Glioblastoma (GB) is a malignant brain tumour that is challenging to treat, often relapsing even after aggressive therapy. Evaluating therapy response relies on magnetic resonance imaging (MRI) following the Response Assessment in Neuro-Oncology (RANO) criteria. However, early assessment is hindered by phenomena such as pseudoprogression and pseudoresponse. Magnetic resonance spectroscopy (MRS/MRSI) provides metabolomics information but is underutilised due to a lack of familiarity and standardisation. Methods: This study explores the potential of spectroscopic imaging (MRSI) in combination with several machine learning approaches, including one-dimensional convolutional neural networks (1D-CNNs), to improve therapy response assessment. Preclinical GB (GL261-bearing mice) were studied for method optimisation and validation. Results: The proposed 1D-CNN models successfully identify different regions of tumours sampled by MRSI, i.e., normal brain (N), control/unresponsive tumour (T), and tumour responding to treatment (R). Class activation maps using Grad-CAM enabled the study of the key areas relevant to the models, providing model explainability. The generated colour-coded maps showing the N, T and R regions were highly accurate (according to Dice scores) when compared against ground truth and outperformed our previous method. Conclusions: The proposed methodology may provide new and better opportunities for therapy response assessment, potentially providing earlier hints of tumour relapsing stages.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Using Single-Voxel Magnetic Resonance Spectroscopy Data Acquired at 1.5T to Classify Multivoxel Data at 3T, A Proof-of-Concept Study

  • Ungan, Gulnur Semahat|||0000-0002-5436-4665
  • Pons-Escoda, Albert|||0000-0003-4167-8291
  • Ulinic, Daniel|||0009-0006-3318-0839
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Vellido, Alfredo|||0000-0002-9843-1911
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
In vivo magnetic resonance spectroscopy (MRS) has two modalities, single-voxel (SV) and multivoxel (MV), in which one or more contiguous grids of SVs are acquired. Purpose: To test whether MV grids can be classified with models trained with SV. Methods: Retrospective study. Training dataset: Multicenter multiformat SV INTERPRET, 1.5T. Testing dataset: MV eTumour, 3T. Two classification tasks were completed: 3-class (meningioma vs. aggressive vs. normal) and 4-class (meningioma vs. low-grade glioma vs. aggressive vs. normal). Five different methods were tested for feature selection. The classification was implemented using linear discriminant analysis (LDA), random forest, and support vector machines. The evaluation was completed with balanced error rate (BER) and area under the curve (AUC) on both sets. The accuracy in class prediction was calculated by developing a solid tumor index (STI) and segmentation accuracy with the Dice score. Results: The best method was sequential forward feature selection combined with LDA, with AUCs = 0.95 (meningioma), 0.89 (aggressive), 0.82 (low-grade glioma), and 0.82 (normal). STI was 66% (4-class task) and 71% (3-class task) because two cases failed completely and two more had suboptimal STI as defined by us. Discussion: The reasons for failure in the classification of the MV test set were related to the presence of artifacts.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Platinum-Based Nanoformulations for Glioblastoma Treatment, The Resurgence of Platinum Drugs?

  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
  • Novio, Fernando|||0000-0002-1517-3612
Current therapies for treating Glioblastoma (GB), and brain tumours in general, are inefficient and represent numerous challenges. In addition to surgical resection, chemotherapy and radiotherapy are presently used as standards of care. However, treated patients still face a dismal prognosis with a median survival below 15-18 months. Temozolomide (TMZ) is the main chemotherapeutic agent administered; however, intrinsic or acquired resistance to TMZ contributes to the limited efficacy of this drug. To circumvent the current drawbacks in GB treatment, a large number of classical and non-classical platinum complexes have been prepared and tested for anticancer activity, especially platinum (IV)-based prodrugs. Platinum complexes, used as alkylating agents in the anticancer chemotherapy of some malignancies, are though often associated with severe systemic toxicity (i.e., neurotoxicity), especially after long-term treatments. The objective of the current developments is to produce novel nanoformulations with improved lipophilicity and passive diffusion, promoting intracellular accumulation, while reducing toxicity and optimizing the concomitant treatment of chemo-/radiotherapy. Moreover, the blood-brain barrier (BBB) prevents the access of the drugs to the brain and accumulation in tumour cells, so it represents a key challenge for GB management. The development of novel nanomedicines with the ability to (i) encapsulate Pt-based drugs and pro-drugs, (ii) cross the BBB, and (iii) specifically target cancer cells represents a promising approach to increase the therapeutic effect of the anticancer drugs and reduce undesired side effects. In this review, a critical discussion is presented concerning different families of nanoparticles able to encapsulate platinum anticancer drugs and their application for GB treatment, emphasizing their potential for increasing the effectiveness of platinum-based drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A comparison of non-negative matrix underapproximation methods for the decomposition of magnetic resonance spectroscopy data from human brain tumors

  • Ungan, Gulnur Semahat|||0000-0002-5436-4665
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Vellido, Alfredo|||0000-0002-9843-1911
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
Magnetic resonance spectroscopy (MRS) is an MR technique that provides information about the biochemistry of tissues in a noninvasive way. MRS has been widely used for the study of brain tumors, both preoperatively and during follow-up. In this study, we investigated the performance of a range of variants of unsupervised matrix factorization methods of the non-negative matrix underapproximation (NMU) family, namely, sparse NMU, global NMU, and recursive NMU, and compared them with convex non-negative matrix factorization (C-NMF), which has previously shown a good performance on brain tumor diagnostic support problems using MRS data. The purpose of the investigation was 2-fold: first, to ascertain the differences among the sources extracted by these methods; and second, to compare the influence of each method in the diagnostic accuracy of the classification of brain tumors, using them as feature extractors. We discovered that, first, NMU variants found meaningful sources in terms of biological interpretability, but representing parts of the spectrum, in contrast to C-NMF; and second, that NMU methods achieved better classification accuracy than C-NMF for the classification tasks when one class was not meningioma.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Advances in the Use of Deep Learning for the Analysis of Magnetic Resonance Image in Neuro-Oncology

  • Pitarch, Carla|||0000-0002-6015-244X
  • Ungan, Gulnur Semahat|||0000-0002-5436-4665
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
  • Vellido, Alfredo|||0000-0002-9843-1911
Machine Learning is entering a phase of maturity, but its medical applications still lag behind in terms of practical use. The field of oncological radiology (and neuro-oncology in particular) is at the forefront of these developments, now boosted by the success of Deep-Learning methods for the analysis of medical images. This paper reviews in detail some of the most recent advances in the use of Deep Learning in this field, from the broader topic of the development of Machine-Learning-based analytical pipelines to specific instantiations of the use of Deep Learning in neuro-oncology; the latter including its use in the groundbreaking field of ultra-low field magnetic resonance imaging.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous

  • Ungan, Gulnur Semahat|||0000-0002-5436-4665
  • Pons-Escoda, Albert|||0000-0003-4167-8291
  • Ulinic, Daniel|||0009-0006-3318-0839
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Ortega-Martorell, Sandra|||0000-0001-9927-3209
  • Olier, Iván|||0000-0002-5679-7501
  • Vellido, Alfredo|||0000-0002-9843-1911
  • Majos, Carles|||0000-0003-0468-5150
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
The standard treatment in glioblastoma includes maximal safe resection followed by concomitant radiotherapy plus chemotherapy and adjuvant temozolomide. The first follow-up study to evaluate treatment response is performed 1 month after concomitant treatment, when contrast-enhancing regions may appear that can correspond to true progression or pseudoprogression. We retrospectively evaluated 31 consecutive patients at the first follow-up after concomitant treatment to check whether the metabolic pattern assessed with multivoxel MRS was predictive of treatment response 2 months later. We extracted the underlying metabolic patterns of the contrast-enhancing regions with a blind-source separation method and mapped them over the reference images. Pattern heterogeneity was calculated using entropy, and association between patterns and outcomes was measured with Cramér's V. We identified three distinct metabolic patterns-proliferative, necrotic, and responsive, which were associated with status 2 months later. Individually, 70% of the patients showed metabolically heterogeneous patterns in the contrast-enhancing regions. Metabolic heterogeneity was not related to the regions' size and only stable patients were less heterogeneous than the rest. Contrast-enhancing regions are also metabolically heterogeneous 1 month after concomitant treatment. This could explain the reported difficulty in finding robust pseudoprogression biomarkers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice

  • Zhao, Kai|||0009-0000-5186-2952
  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Bopp, Miriam H.A.|||0000-0003-1574-7572
  • Möschl, Vincent
  • Pagenstecher, Axel|||0000-0001-9627-6439
  • Mulero-Acevedo, Marta|||0000-0002-3600-8907
  • Vázquez, Mario
  • Barcia, Carlos|||0000-0003-0976-4245
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Nimsky, Christopher|||0000-0002-8216-9410
  • Rusch, Tillmann|||0009-0007-4848-5464
  • Bartsch, Joerg Walter.|||0000-0002-2773-3357
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
The tumor microenvironment in glioblastoma (GB) is considered to be "cold", i.e., the fraction of cytotoxic T cells, for instance, is low. Instead, macrophages are the major immune cell population in GB, which stem either from tissue response (resident microglia) or recruitment of macrophages from the periphery, thereby undergoing tumor-dependent "imprinting" mechanisms by which macrophages can adapt a tumor-supportive phenotype. In this regard, it is important to describe the nature of macrophages associated with GB, in particular under therapy conditions using the gold standard chemotherapy drug temozolomide (TMZ). Here, we explored the suitability of combining information from in vivo magnetic resonance spectroscopic (MRS) approaches (metabolomics) with in vitro molecular analyses to assess therapy response and characterize macrophage populations in mouse GB using an isogenic GL261 model. For macrophage profiling, expression levels of matrix metalloproteinases (MMPs) and A disintegrin and metalloproteinases (ADAMs) were determined, since their gene products affect macrophage-tumor cell communication by extensive cleavage of immunomodulatory membrane proteins, such as PD-L1. In tumor mice with an overall therapy response, expression of genes encoding the proteases ADAM8, ADAM10, and ADAM17 was increased and might contribute to the immunosuppressive phenotype of GB and immune cells. In tumors responding to therapy, expression levels of ADAM8 were upregulated by TMZ, and higher levels of PD-L1 were correlated significantly. Using a CRISPR/Cas9 knockout of ADAM8 in GL261 cells, we demonstrated that soluble PD-L1 (sPD-L1) is only generated in the presence of ADAM8. Moreover, primary macrophages from WT and ADAM8-deficient mice showed ADAM8-dependent release of sPD-L1, independent of the macrophage polarization state. Since ADAM8 expression is induced in responding tumors and PD-L1 shedding is likely to decrease the anti-tumor activities of T-cells, we conclude that immunotherapy resistance is caused, at least in part, by the increased presence of proteases, such as ADAM8.